Payment overview · 2025
General Payments
$1,340.47
26 reported records · 9 companies
Healthcare provider profile · identity verified
Antonio Reyes, MD
Allopathic & Osteopathic Physicians|Urology · PEMBROKE PINES, FL · NPI 1174584809
Verified facts
What the public records show
CMS Open Payments records show Antonio Reyes, MD received $1,340.47 in general payments during 2025 across 26 reported records.
COLOPLAST CORP accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Erleada.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Erleada by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $737.08 | 55.0% | 8 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $260.73 | 19.4% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $122.31 | 9.1% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $76.59 | 5.7% | 2 | 2025 |
| BIOTISSUE HOLDINGS INC. | Unresolved — no canonical attribution shown | $38.01 | 2.8% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $30.58 | 2.3% | 1 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $26.83 | 2.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $25.32 | 1.9% | 1 | 2025 |
| Myriad Genetic Laboratories, Inc. | Unresolved — no canonical attribution shown | $23.02 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $901.06 | 24 |
| Travel and Lodging | $439.41 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Titan Normalized: titan |
Device | COLOPLAST CORP | $737.08 | 8 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc. | $138.90 | 5 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $122.31 | 5 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $122.31 | 5 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| LithoVue Elite Normalized: lithovue elite |
Device | Boston Scientific Corporation | $50.14 | 1 | 2025 |
Source payment records
|
|||||
| PLUVICTO Normalized: pluvicto |
Drug | Novartis Pharmaceuticals Corporation | $30.58 | 1 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $26.83 | 1 | 2025 |
Source payment records
|
|||||
| LithoVue Normalized: lithovue |
Device | Boston Scientific Corporation | $26.45 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $25.32 | 1 | 2025 |
Source payment records
|
|||||
| PROLARIS Normalized: prolaris |
Device | Myriad Genetic Laboratories, Inc. | $23.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ERLEADA erleada |
2025 | Erleada | 2024 | 40 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Finasteride | Finasteride | 874 | 328 |
| Tamsulosin Hcl | Tamsulosin Hcl | 625 | 250 |
| Sildenafil Citrate | Sildenafil Citrate | 378 | 119 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 267 | 198 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 220 | 89 |
| Methenamine Hippurate | Methenamine Hippurate | 213 | 57 |
| Myrbetriq | Mirabegron | 161 | 55 |
| Tadalafil | Tadalafil | 128 | 39 |
| Cephalexin | Cephalexin | 115 | 48 |
| Ketoconazole | Ketoconazole | 97 | 38 |
| Estradiol | Estradiol | 89 | 56 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 79 | 22 |
| Testosterone Cypionate | Testosterone Cypionate | 71 | 23 |
| Gemtesa | Vibegron | 61 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 60 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 59 | 23 |
| Dutasteride | Dutasteride | 51 | 21 |
| Pentoxifylline | Pentoxifylline | 48 | 14 |
| Potassium Citrate Er | Potassium Citrate | 46 | 24 |
| Erleada | Apalutamide | 40 | suppressed |
| Premarin | Estrogens, Conjugated | 36 | 24 |
| Cefdinir | Cefdinir | 33 | 30 |
| Bicalutamide | Bicalutamide | 26 | 11 |
| Allopurinol | Allopurinol | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 11 |
| Xtandi | Enzalutamide | 23 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 17 |
| Trospium Chloride | Trospium Chloride | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Silodosin | Silodosin | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Clomid | Clomiphene Citrate | 12 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
| Sodium Citrate-Citric Acid | Citric Acid/Sodium Citrate | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,340.47 · 26 records | COLOPLAST CORP | CARVYKTI, ELIGARD, ERLEADA, JATENZO, LithoVue, LithoVue Elite, Nubeqa, PLUVICTO, PROLARIS, PROVENGE, RYBREVANT, Titan, Xofigo | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Erleada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Janssen Biotech, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error